Most strikingly, we demonstrate a synergistic effect of ERBB2 and anti-PD-1 targeted treatments that elicit profound responses in preclinical SCLC models, suggesting this combination for future clinical trials in patients with SCLC. The gene discussed is ERBB2; the disease is small cell lung carcinoma.